J Gregory Cairncross

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. ncbi request reprint Imaging molecular signatures in oligodendroglioma
    J Gregory Cairncross
    Department of Clinical Neurosciences, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Clin Cancer Res 10:7109-11. 2004
  2. pmc Sensitivity to temozolomide in brain tumor initiating cells
    Michael D Blough
    Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada
    Neuro Oncol 12:756-60. 2010
  3. pmc Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402
    Gregory Cairncross
    Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada T2N 2T9
    J Clin Oncol 31:337-43. 2013
  4. ncbi request reprint Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
    Gregory Cairncross
    University of Calgary, Calgary, Alberta, Canada E mail
    J Clin Oncol 24:2707-14. 2006
  5. doi request reprint Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma
    Gregory Cairncross
    Department of Clinical Neurosciences and Hotchkiss Brain, Institute, University of Calgary, Calgary, Alberta, Canada
    Cancer J 14:352-7. 2008
  6. pmc On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells
    Owen D Stechishin
    Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Neuro Oncol 15:198-207. 2013
  7. pmc Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin
    Franz J Zemp
    Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Southern Alberta Cancer Research Institute, Calgary, Canada
    Neuro Oncol 15:904-20. 2013
  8. pmc Leptomeningeal disease in oligodendroglial tumors: a population-based study
    Gloria Roldan
    Clark H Smith Brain Tumor Center, Tom Baker Cancer Center, Alberta Health Services, HRIC 2AA07, 3330 Hospital Dr NW, Calgary, AB, T2N 4N1, Canada
    J Neurooncol 104:811-5. 2011
  9. ncbi request reprint Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis
    Gloria Roldan
    Department of Oncology, Tom Baker Cancer Centre, Alberta Cancer Board, University of Calgary, Calgary, Alberta Canada
    Can J Neurol Sci 35:204-9. 2008
  10. ncbi request reprint Predicting MGMT methylation status of glioblastomas from MRI texture
    Ilya Levner
    Department of Radiology, University of Calgary, Alberta, Canada
    Med Image Comput Comput Assist Interv 12:522-30. 2009

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Imaging molecular signatures in oligodendroglioma
    J Gregory Cairncross
    Department of Clinical Neurosciences, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Clin Cancer Res 10:7109-11. 2004
  2. pmc Sensitivity to temozolomide in brain tumor initiating cells
    Michael D Blough
    Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada
    Neuro Oncol 12:756-60. 2010
    ..BTICs are not uniformly resistant to TMZ; some are sensitive. MGMT status does not predict TMZ response with high precision...
  3. pmc Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402
    Gregory Cairncross
    Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada T2N 2T9
    J Clin Oncol 31:337-43. 2013
    ..Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown...
  4. ncbi request reprint Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
    Gregory Cairncross
    University of Calgary, Calgary, Alberta, Canada E mail
    J Clin Oncol 24:2707-14. 2006
    ..Furthermore, better outcomes in AO have been associated with 1p and 19q allelic loss...
  5. doi request reprint Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma
    Gregory Cairncross
    Department of Clinical Neurosciences and Hotchkiss Brain, Institute, University of Calgary, Calgary, Alberta, Canada
    Cancer J 14:352-7. 2008
    ....
  6. pmc On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells
    Owen D Stechishin
    Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    Neuro Oncol 15:198-207. 2013
    ..Here, we used a large set of molecularly heterogeneous BTSCs to evaluate the translational potential of JAK2/STAT3 therapeutics...
  7. pmc Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin
    Franz J Zemp
    Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Southern Alberta Cancer Research Institute, Calgary, Canada
    Neuro Oncol 15:904-20. 2013
    ..In this study, we investigate the oncolytic potential of myxoma virus (MYXV) alone and in combination with rapamycin in vitro and in vivo using human brain tumor-initiating cells (BTICs)...
  8. pmc Leptomeningeal disease in oligodendroglial tumors: a population-based study
    Gloria Roldan
    Clark H Smith Brain Tumor Center, Tom Baker Cancer Center, Alberta Health Services, HRIC 2AA07, 3330 Hospital Dr NW, Calgary, AB, T2N 4N1, Canada
    J Neurooncol 104:811-5. 2011
    ..Treatment with oral chemotherapy seemed as effective as more aggressive treatments (e.g. repeat RT or intrathecal chemotherapy) in these patients...
  9. ncbi request reprint Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis
    Gloria Roldan
    Department of Oncology, Tom Baker Cancer Centre, Alberta Cancer Board, University of Calgary, Calgary, Alberta Canada
    Can J Neurol Sci 35:204-9. 2008
    ..A long surviving case led us to review our experience with LMD in patients with oligodendrogliomas...
  10. ncbi request reprint Predicting MGMT methylation status of glioblastomas from MRI texture
    Ilya Levner
    Department of Radiology, University of Calgary, Alberta, Canada
    Med Image Comput Comput Assist Interv 12:522-30. 2009
    ..Blinded classification of MGMT promoter methylation status reached an average accuracy of 87.7%, indicating that the proposed technique is accurate enough for clinical use...
  11. doi request reprint DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma
    Michael D Blough
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Ann Neurol 71:845-9. 2012
    ..Our findings show for the first time that the pH regulator NHE-1 can be silenced in a human cancer and also suggest that pH deregulation may contribute to the distinctive biology of human oligodendroglioma...
  12. doi request reprint Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma
    Michael D Blough
    Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    J Neurooncol 102:1-7. 2011
    ..P53 status may influence response to TMZ in differentiated cells in a GBM with a negligible affect on its initiating cells...
  13. doi request reprint Methylation status of MGMT gene promoter in meningiomas
    Paula de Robles
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Cancer Genet Cytogenet 187:25-7. 2008
    ..None of the meningiomas in our series showed MGMT gene promoter methylation. Based on these data, we conclude that there is no biological rational to suggest that TMZ might have significant anti-meningioma activity...
  14. ncbi request reprint Population-based study of pseudoprogression after chemoradiotherapy in GBM
    Gloria B Roldán
    Department of Oncology, Tom Baker Cancer Centre, Alberta Cancer Board, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    Can J Neurol Sci 36:617-22. 2009
    ..Little is known about the natural history of radiographic pseudoprogression...
  15. doi request reprint An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging
    Sylvia Drabycz
    Department of Electrical and Computer Engineering, University of Calgary, Alberta, Canada
    Neuroimage 49:1398-405. 2010
    ....
  16. pmc An in vivo patient-derived model of endogenous IDH1-mutant glioma
    H Artee Luchman
    Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
    Neuro Oncol 14:184-91. 2012
    ....
  17. pmc Oligodendroglioma cell lines containing t(1;19)(q10;p10)
    John J P Kelly
    Faculty of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
    Neuro Oncol 12:745-55. 2010
    ..These lines may be important tools for understanding the biology of oligodendrogliomas and the function of their defining genetic traits...
  18. doi request reprint Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience
    Shelly Lwu
    Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    J Neurooncol 96:403-8. 2010
    ..Increased awareness of practice guidelines may help modify AED prescription patterns in malignant glioma patients...
  19. ncbi request reprint Population-based study of medulloblastoma: outcomes in Alberta from 1975 to 1996
    Gloria Roldan
    Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada
    Can J Neurol Sci 35:210-5. 2008
    ..Collins' Law dictates that 'cure' of a child with a tumor occurs after a period that includes the child's age at diagnosis plus 9 months...
  20. doi request reprint The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma
    Robert Brown
    Department of Electrical and Computer Engineering, University of Calgary, Calgary, Alberta, Canada
    Clin Cancer Res 14:2357-62. 2008
    ..Some patients with low-grade glioma have extraordinarily long survival times; current, early treatment does not prolong their lives. For this reason, therapies that sometimes have neurologic side effects are often deferred intentionally...
  21. doi request reprint Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens
    John J P Kelly
    Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
    Stem Cells 27:1722-33. 2009
    ..This novel experimental system will permit the elucidation of additional constitutively activated mechanisms that promote GBM BTSC survival, self-renewal, and proliferation...
  22. pmc A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes
    Tara Spence
    Corresponding authors Jennifer A Chan, MD, Department of Pathology and Laboratory Medicine, University of Calgary, HRIC 2A25, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1 Annie Huang, MD, PhD, Division of Hematology Oncology, Department of Pediatrics, The Hospital for Sick Children, TMDT, 11 401P, 101 College St, Toronto, Ontario, Canada M5G 1L7
    Neuro Oncol 16:62-71. 2014
    ..41-42, expression of the RNA binding protein Lin28, and dismal prognosis. Functional and therapeutic studies of ETMR have been limited by a lack of model systems...
  23. ncbi request reprint O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells
    Michael D Blough
    Department of Clinical Neurosciences, University of Calgary and the Southern Alberta Cancer Research Institute, Calgary, Alberta, Canada
    Cancer Res 67:580-4. 2007
    ..These results imply that the best use of temozolomide requires a thorough understanding of MGMT regulation...
  24. ncbi request reprint Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?
    Donna Senger
    Department of Oncology and Clinical Neurosciences, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta
    Cancer J 9:214-21. 2003
    ..We conclude by suggesting a translational research strategy that is aimed at uncovering the molecular signatures of long survivorship...
  25. doi request reprint A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
    Peter Forsyth
    Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Mol Ther 16:627-32. 2008
    ..Median TTP was 4.3 weeks (range, 2.6-39). An MTD was not reached. The intratumoral administration of the genetically unmodified reovirus was well tolerated using these doses and schedule, in patients with recurrent MG...
  26. ncbi request reprint Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group
    Marc Webster
    Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Invest New Drugs 23:591-6. 2005
    ..A multi-centre phase II study of SarCNU-a novel chloroethylnitrosourea (CNU)-in patients with recurrent malignant glioma to assess response rate, survival and effects of treatment...
  27. ncbi request reprint Imaging correlates of molecular signatures in oligodendrogliomas
    Joseph F Megyesi
    Department of Clinical Neurological Sciences, University of Western Ontario and London Regional Cancer Centre, London, Ontario, Canada
    Clin Cancer Res 10:4303-6. 2004
    ..These data encourage prospective evaluation of molecular alterations and magnetic resonance imaging characteristics of glial neoplasms...
  28. ncbi request reprint The use of frailty hazard models for unrecognized heterogeneity that interacts with treatment: considerations of efficiency and power
    Yi Li
    Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Biometrics 58:232-6. 2002
    ..Further, there may be a substantial loss of power in the presence of the frailty with or without an interaction with treatment...
  29. pmc High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 8:183-8. 2006
    ..This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia...
  30. ncbi request reprint Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma"
    Hikaru Sasaki
    Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    J Neuropathol Exp Neurol 61:58-63. 2002
    ..As a result, such objective molecular genetic analyses should be incorporated into patient management and into clinical trials of low-grade diffuse gliomas...
  31. ncbi request reprint High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Neurooncol 65:127-34. 2003
    ....
  32. ncbi request reprint Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    N Engl J Med 352:987-96. 2005
    ..In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety...
  33. ncbi request reprint MGMT gene silencing and benefit from temozolomide in glioblastoma
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
    N Engl J Med 352:997-1003. 2005
    ....
  34. ncbi request reprint Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases
    Christopher J Watling
    Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada
    J Neurosurg 97:224-6. 2002
    ..Acetazolamide, an orally administered carbonic anhydrase inhibitor, appears to be a specific and effective therapy for this uncommon neurological disorder...
  35. ncbi request reprint Influence of unrecognized molecular heterogeneity on randomized clinical trials
    Rebecca A Betensky
    Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA
    J Clin Oncol 20:2495-9. 2002
    ..Despite this reliance on histology and the assumption that histology defines the disease, underlying molecular heterogeneity likely differentiates among patients' outcomes...
  36. ncbi request reprint Adjuvant chemotherapy for adults with malignant glioma: a systematic review
    James Perry
    Odette Cancer Centre, Sunnybrook Health Sciences Centre Toronto, Ontario, Canada
    Can J Neurol Sci 34:402-10. 2007
    ..This systematic review examines the role of chemotherapy following surgery and external beam radiotherapy for adults with newly diagnosed malignant glioma...
  37. ncbi request reprint Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide
    G Wei Xu
    Department of Oncology, University of Western Ontario, London, Ontario
    Int J Cancer 116:187-92. 2005
    ....
  38. ncbi request reprint Ki-67: a prognostic factor for low-grade glioma?
    Barbara J Fisher
    Department of Radiation Oncology, London Regional Cancer Centre and University of Western Ontario, London, Ontario, Canada
    Int J Radiat Oncol Biol Phys 52:996-1001. 2002
    ..Immunohistochemical techniques were used to detect the expression of Ki-67, a nuclear proliferation marker, in 180 low-grade glioma tumor specimens to determine whether Ki-67 is a prognostic predictor of survival or tumor recurrence...
  39. ncbi request reprint DMBT1 polymorphisms: relationship to malignant glioma tumorigenesis
    Hikaru Sasaki
    Molecular Neuro Oncology and Pathology Laboratories, Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129, USA
    Cancer Res 62:1790-6. 2002
    ..These data suggest that DMBT1 polymorphisms are not likely primary targets of 10q loss in malignant gliomas and do not support a major role for DMBT1 in gliomagenesis...
  40. ncbi request reprint Tests of association under misclassification: application to histological sampling in oncology
    Rebecca A Betensky
    Department of Biostatistics, Harvard School of Public Health, 655 Huntington Ave, Boston, MA 02115, USA
    Stat Med 26:4808-16. 2007
    ..In this study, calcification, a feature related to the imaging parameters, was potentially misclassified as not present...
  41. pmc Survey of treatment recommendations for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 9:314-8. 2007
    ....
  42. pmc Recent developments in the molecular characterization and treatment of oligodendroglial tumors
    Martin van den Bent
    Department of Neuro Oncology, Dr Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands
    Neuro Oncol 5:128-38. 2003
    ..Further studies are needed to confirm the efficacy and safety profile of temozolomide and to determine the optimal dose and schedule for treating ODs...
  43. ncbi request reprint Gene expression-based classification of malignant gliomas correlates better with survival than histological classification
    Catherine L Nutt
    Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 63:1602-7. 2003
    ..These data suggest that class prediction models, based on defined molecular profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than does standard pathology...
  44. doi request reprint Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
    Anastasia Murat
    Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne 1011, Switzerland
    J Clin Oncol 26:3015-24. 2008
    ..Here, we aimed to identify molecular profiles specific for treatment resistance to the current standard of care of concomitant chemoradiotherapy with the alkylating agent temozolomide...
  45. doi request reprint Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas
    Warren P Mason
    Department of Medicine, The University of Toronto, Toronto, Ontario, Canada
    Neurology 71:365-73. 2008
    ..Time will tell whether these new agents can be successfully introduced into the clinical arena. In the meantime, the molecular characteristics of gliomas are being used to select patients for both randomized trials and phase II studies...
  46. ncbi request reprint Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial
    Warren P Mason
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Nat Clin Pract Neurol 1:88-95. 2005
    ....
  47. doi request reprint Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme
    Angelique E Sijben
    Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
    J Neurooncol 89:97-103. 2008
    ..Elderly patients have glioblastomas (GBM) that are aggressive and poorly responsive to treatment. They are also prone to the side effects of treatment of GBM...
  48. doi request reprint Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402
    Caterina Giannini
    Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Brain Pathol 18:360-9. 2008
    ..3 years in RT group. These findings suggest that classic oligodendroglial morphology combined with 1p 19q deletion may in the future be predictive of chemotherapeutic response and survival...
  49. ncbi request reprint Changing paradigms--an update on the multidisciplinary management of malignant glioma
    Roger Stupp
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
    Oncologist 11:165-80. 2006
    ..This review summarizes recent developments, focusing on the clinical management of patients in daily neuro-oncology practice...
  50. ncbi request reprint Analysis of a molecular genetic neuro-oncology study with partially biased selection
    Rebecca A Betensky
    Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA
    Biostatistics 4:167-78. 2003
    ..Here we examine approaches for utilizing the entire study population, as well as the assumptions required for doing so. We illustrate that there are both costs and benefits to using the 25 selected patients...
  51. ncbi request reprint Glioma therapies: how to tell which work?
    James R Perry
    J Clin Oncol 21:3547-9. 2003
  52. ncbi request reprint Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
    Thierry Gorlia
    EORTC Data Centre, Brussels, Belgium
    Lancet Oncol 9:29-38. 2008
    ....